R

RARE

RARE

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
0%Bearish
Buy/Sell Ratio0% buys
BearishBullish
RARE Live QuoteReal-time
$16.48
+$0.53(+3.32%)1M
Day Range$16.43 – $17.35
Open$16.94
Previous Close$17.22
Volume3.01M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$1.76B
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-5.17
Price to Book19.7
Dividend Yield0.65%
Beta (Volatility)0.36
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $16.48 (14%)
Low: $12.73High: $39.89
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$24.80-83.5% upside

Insider Buys

0

$0

Insider Sales

42

$11.98M

Total Volume

$11.98M

42 transactions

Net Activity

$11.98M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
15CONFIDENCE

Sentiment Rating

Heavy Distribution

CEO Conviction Index

Liquidating / Profit Taking

Key Drivers

  • •Heavy distribution: sales represent 100% of total transaction value.
  • •CEO selling activity detected. Often driven by option expiration or diversification plans.
  • •Significant liquidation: total sale value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
K
1

Kakkis Emil D

Pres, CEO

0 buys4 sells

$6.30M total

H
2

Horn Howard

CFO

0 buys12 sells

$1.51M total

P
3

Parschauer Karah Herdman

EVP, GC

0 buys7 sells

$1.23M total

H
4

Harris Erik

EVP, Chief Commercial Officer

0 buys2 sells

$876K total

P
5

Pinion John Richard

See Remarks

0 buys2 sells

$837K total

Trading History
RARE insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Oct 15, 2026

1 months ago

Horn Howard

CFO

CFO
Sell7.1K$15.27$108K

Sep 15, 2026

2 months ago

Huizenga Theodore Alan

SVP, Chief Accounting Officer

SVP
Sell1.3K$13.57$17K

Sep 3, 2026

2 months ago

Huizenga Theodore Alan

SVP, Chief Accounting Officer

SVP
Sell161$13.99$2K

Aug 3, 2026

3 months ago

Parschauer Karah Herdman

EVP, GC

EVP
Sell1.9K$24.92$47K

Aug 3, 2026

3 months ago

Horn Howard

CFO

CFO
Sell4.7K$24.92$117K

Jul 1, 2026

4 months ago

Horn Howard

CFO

CFO
Sell4.7K$33.13$156K

Jun 15, 2026

5 months ago

Sanders Corazon (Corsee) D.

Dir

Director
Sell2.0K$25.05$50K

Jun 15, 2026

5 months ago

Parschauer Karah Herdman

EVP, GC

EVP
Sell1.9K$24.62$47K

Jun 1, 2026

5 months ago

Horn Howard

CFO

CFO
Sell4.7K$23.77$111K

May 18, 2026

6 months ago

Suliman Shehnaaz

Dir

Director
Sell5.7K$25.12$144K

May 5, 2026

6 months ago

Crombez Eric

EVP, Chief Medical Officer

EVP
Sell344$24.96$9K

May 1, 2026

6 months ago

Horn Howard

CFO

CFO
Sell4.7K$24.90$117K

Apr 1, 2026

7 months ago

Horn Howard

CFO

CFO
Sell4.7K$20.97$98K

Mar 6, 2026

8 months ago

Parschauer Karah Herdman

EVP, GC

EVP
Sell9.5K$21.87$208K

Mar 2, 2026

8 months ago

Pinion John Richard

See Remarks

Insider
Sell10.0K$22.80$229K

Mar 2, 2026

8 months ago

Harris Erik

EVP, Chief Commercial Officer

EVP
Sell10.5K$22.80$240K

Mar 2, 2026

8 months ago

Kakkis Emil D

Pres, CEO

CEO
Sell54.4K$22.80$1.24M

Mar 2, 2026

8 months ago

Parschauer Karah Herdman

EVP, GC

EVP
Sell8.1K$22.80$185K

Mar 2, 2026

8 months ago

Huizenga Theodore Alan

SVP, Chief Accounting Officer

SVP
Sell1.6K$22.80$37K

Mar 2, 2026

8 months ago

Horn Howard

CFO

CFO
Sell10.0K$22.65$228K

Mar 2, 2026

8 months ago

Crombez Eric

EVP, Chief Medical Officer

EVP
Sell7.0K$22.80$160K

Feb 2, 2026

9 months ago

Horn Howard

CFO

CFO
Sell3.1K$23.56$72K

Jan 2, 2026

10 months ago

Horn Howard

CFO

CFO
Sell3.1K$22.84$72K

Dec 29, 2025

10 months ago

Huizenga Theodore Alan

SVP, Chief Accounting Officer

SVP
Sell85$34.38$3K

Dec 10, 2025

11 months ago

Horn Howard

CFO

CFO
Sell3.1K$36.38$112K

Oct 13, 2025

13 months ago

Horn Howard

CFO

CFO
Sell7.9K$31.51$250K

Sep 18, 2025

14 months ago

Huizenga Theodore Alan

SVP, Chief Accounting Officer

SVP
Sell64$29.17$2K

Sep 12, 2025

14 months ago

Parschauer Karah Herdman

EVP, GC

EVP
Sell2.5K$31.17$76K

Sep 5, 2025

14 months ago

Huizenga Theodore Alan

SVP, Chief Accounting Officer

SVP
Sell84$31.39$3K

Jun 20, 2025

17 months ago

Sanders Corazon (Corsee) D.

Dir

Director
Sell2.4K$37.39$90K

Apr 21, 2025

19 months ago

Crombez Eric

EVP, Chief Medical Officer

EVP
Sell762$37.93$29K

Mar 6, 2025

20 months ago

Horn Howard

CFO

CFO
Sell1.8K$40.40$72K

Mar 3, 2025

20 months ago

Kassberg Thomas Richard

CBO, EVP

EVP
Sell6.0K$42.10$254K

Mar 3, 2025

20 months ago

Parschauer Karah Herdman

EVP, GC

EVP
Sell12.8K$42.10$541K

Mar 3, 2025

20 months ago

Crombez Eric

EVP, Chief Medical Officer

EVP
Sell8.9K$42.10$377K

Mar 3, 2025

20 months ago

Pinion John Richard

See Remarks

Insider
Sell14.4K$42.10$608K

Mar 3, 2025

20 months ago

Kakkis Emil D

Pres, CEO

CEO
Sell98.4K$42.20$4.15M

Mar 3, 2025

20 months ago

Harris Erik

EVP, Chief Commercial Officer

EVP
Sell15.1K$42.10$636K

Mar 3, 2025

20 months ago

Huizenga Theodore Alan

SVP, Chief Accounting Officer

SVP
Sell967$42.10$41K

Feb 27, 2025

21 months ago

Parschauer Karah Herdman

EVP, GC

EVP
Sell3.0K$42.88$128K

Dec 30, 2024

23 months ago

Kakkis Emil D

Pres, CEO

CEO
Sell11.7K$42.23$495K

Dec 10, 2024

23 months ago

Kakkis Emil D

Pres, CEO

CEO
Sell8.3K$50.00$414K
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
RARE Buy Conviction0%
Industry Rank#0 of 569
Volume Contribution0.1%
Total Industry Activity$16.52B

RARE has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for RARE

Over the last 90 days, corporate insiders at RARE (RARE) engaged in a total of 42 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 42 were sales. The total volume of insider trading reached $11.98M.

The net insider activity for RARE shows a net selling bias of $11.98M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Kakkis Emil D (Pres, CEO), who traded 98.4K shares valued at $4.15M on Mar 3, 2025.

Live Market News & Developments
Aggregated real-time headlines for RARE (RARE)
6 updates

Why USA Rare Earth Stock Is Rising Today

Yahoo FinanceYesterday

Why USA Rare Earth Stock Is Rising Today

The Motley FoolYesterday

USA Rare Earth Rises 5%, MP Materials Gains 3%, Critical Metals Dips: Can Trump's Pledge to "Catch" China on Rare Earths Revive the Sector?

24/7 Wall St.Yesterday

Lumentum: AI Fear Is Creating A Rare Buying Opportunity

Seeking Alpha2d ago

USA Rare Earth Stock Rises as Director Buys $3 Million of Shares

TradingViewYesterday

Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

Pharmaceutical Executive43d ago

FAQs About RARE Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for RARE.

Based on SEC Form 4 disclosures, the Insider Confidence Score for RARE is currently 15/100, which reflects a heavy distribution bias. This calculation accounts for a total of 0 purchases and 42 sales by company executives over the last 90 days.

The CEO Conviction Index for RARE is rated as "Liquidating / Profit Taking". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.